公开(公告)号：US20240294672A1

公开(公告)日：2024-09-05

申请号：US18590651

申请日：2024-02-28

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Junichi Nezu ,  Takahiro Ishiguro ,  Atsushi Narita ,  Akihisa Sakamoto ,  Yumiko Kawai ,  Tomoyuki Igawa ,  Taichi Kuramochi

IPC: C07K16/46 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/46 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/303 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

Abstract: Disclosed are bispecific antibodies with heavy chain constant regions having the sequence of an IgG1 constant region with one or more mutations including one or more substitutions that reduce the ability of the heavy chain constant regions to bind to a human Fcγ receptor.

公开(公告)号：US20240294638A1

公开(公告)日：2024-09-05

申请号：US18661970

申请日：2024-05-13

Applicant: LES LABORATOIRES SERVIER

Inventor： Randi Westh Hansen ,  Franziska Katharina Uhlenbrock ,  Nikolaj Dietrich ,  Anne Worsaae ,  Michael Monrad Grandal

IPC: C07K16/28 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K45/06 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention relates to anti-NKG2A antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.

公开(公告)号：US12077601B2

公开(公告)日：2024-09-03

申请号：US17379739

申请日：2021-07-19

Applicant: Banyan Biomarkers, Inc.

Inventor： Michael Catania ,  Ronald L. Hayes

IPC: C07K16/40 ,  A61B5/00 ,  A61B5/055 ,  A61B6/03 ,  A61B6/50 ,  A61P25/00 ,  C07K16/18 ,  G01N33/68 ,  A61B6/00

CPC classification number: C07K16/40 ,  A61B5/0042 ,  A61B5/055 ,  A61B6/032 ,  A61B6/501 ,  A61P25/00 ,  C07K16/18 ,  G01N33/6896 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.

公开(公告)号：US12077597B2

公开(公告)日：2024-09-03

申请号：US17534707

申请日：2021-11-24

Applicant: INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH

Inventor： Claudine Vermot-Desroches ,  Hélène Rouquette ,  Benoît Milcent

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734

Abstract: Novels antibodies, preferably monoclonal antibodies, or antigen-binding fragments thereof, said antibody or fragment thereof specifically binding to CD5. These antibodies may be used as a medicament, especially in the treatment of diseases in immunomodulation, inflammation, virology, infectiology, autoimmunity and oncology domains. Immune cells and/or cancer cells targeted by the invention are expressing CD5 antigen. These antibodies may be in particular chimeric or humanized. The invention also relates to pharmaceutical compositions, such as immunomodulator, anti-cancerous and anti-infectious compositions, containing such an antibody or antigen-binding fragment and methods of use of these, either for laboratory work, in drug manufacturing, such as in cell therapy cells production, or for medical treatment.

公开(公告)号：US12071471B2

公开(公告)日：2024-08-27

申请号：US15978801

申请日：2018-05-14

Applicant: COVALENT BIOSCIENCE INCORPORATED

Inventor： Sudhir Paul ,  Stephanie Planque ,  Yasuhiro Nishiyama ,  Eric L. Brown ,  Keri C. Smith ,  Hiroaki Taguchi

IPC: C07K16/18 ,  C07K16/10 ,  C07K16/12 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/18 ,  C07K16/1063 ,  C07K16/109 ,  C07K16/1271 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622

Abstract: Disclosed are antibodies (immunoglobulins) and fragments thereof that hydrolyze or bind polypeptide antigens belonging to Staphylococcus aureus, hepatitis C virus, human immunodeficiency virus and Alzheimer's disease. Also disclosed are novel methods to improve the antigen reactivity of the immunoglobulins and to treat a pathophysiological condition using the immunoglobulins as therapeutics.

公开(公告)号：US20240279346A1

公开(公告)日：2024-08-22

申请号：US18582950

申请日：2024-02-21

Applicant: Immunitas Therapeutics, Inc.

Inventor： Alison TISDALE ,  Uli BIALUCHA ,  George PUNKOSDY ,  Alexandria FUSCO ,  Frano IRVINE ,  Emily ROSENTRATER ,  Elizabeth SCANLON ,  Michael BATTLES

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  G01N33/68

CPC classification number: C07K16/2851 ,  A61P35/00 ,  A61P37/04 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  G01N2333/70596 ,  G01N2800/52

Abstract: The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies

公开(公告)号：US20240279325A1

公开(公告)日：2024-08-22

申请号：US18480730

申请日：2023-10-04

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Tomoyuki Igawa ,  Atsuhiko Maeda ,  Shigero Tamba ,  Takeshisa Kitazawa ,  Takeshi Baba ,  Yoshinao Ruike ,  Junichi Nezu

IPC: C07K16/24 ,  A61K39/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28

CPC classification number: C07K16/24 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/248 ,  C07K16/2866 ,  A61K2039/505 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

公开(公告)号：US20240279314A1

公开(公告)日：2024-08-22

申请号：US18618981

申请日：2024-03-27

Applicant: The Rockefeller University

Inventor： Jeffrey Ravetch ,  Falk Nimmerjahn ,  Yoshikatsu Kaneko

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/06 ,  C07K16/18 ,  C12P21/00 ,  G01N33/68

CPC classification number: C07K16/00 ,  A61K47/68 ,  C07K16/06 ,  C07K16/18 ,  C12P21/005 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76

Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.

公开(公告)号：US20240276959A1

公开(公告)日：2024-08-22

申请号：US18540440

申请日：2023-12-14

Applicant: Roger Kingdon Craig ,  ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM

Inventor： Roger Kingdon Craig ,  Franklin Gerardus Grosveld ,  Richard Wilhelm Janssens ,  Marinus Johannes Van Haperen

IPC: A01K67/0278 ,  A01K67/0276 ,  C12N15/85 ,  C12P21/00

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C12P21/005 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C12N15/8509

Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.

公开(公告)号：US12065508B2

公开(公告)日：2024-08-20

申请号：US17716830

申请日：2022-04-08

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lauric Haber ,  Jennifer A. Finney ,  Ryan McKay ,  Eric Smith ,  Chia-Yang Lin

IPC: A61K39/395 ,  C07K14/725 ,  C07K14/74 ,  C07K16/46

CPC classification number: C07K16/468 ,  C07K14/7051 ,  C07K14/70539 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622

Abstract: The present invention provides multispecific antigen-binding molecules that bind both a T-cell antigen (e.g., CD3) and a target antigen (e.g., a tumor associated antigen, a viral or bacterial antigen), and which include a single polypeptide chain that is multivalent (e.g., bivalent) with respect to T-cell antigen binding, and uses thereof.